Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Also in global health news: Africa measles eradication; water, food security in South Asia; MDR-TB in Mumbai; SADC summit; U.S. Cuba embargo

WHO Regional Director for Africa Luis Gomes Sambo said Tuesday during the 59th Session of the WHO Regional Committee for Africa in Kigali, Rwanda, that measles could be eradicated from the continent by 2020, citing an 89 percent reduction in the number of deaths caused by measles between 2000 and 2007, Angencia AngolaPress reports.

4 Sep 2009

Adding screens to homes can cut malaria risk, study says

A study conducted in the Republic of The Gambia found that adding screens to the windows and doors of houses can help reduce the number of malaria-carrying mosquitoes inside and prevent anaemia in children, CBCnews.ca reports (9/2).

4 Sep 2009

Mosquito screens prevent malaria

Trials of a screen-based malaria prevention programme in 500 homes in The Gambia, Africa, have led to a 50 per cent reduction in malaria transmission and anaemia in children. A child dies from malaria in Africa every 30 seconds and infection can lead to an increased risk of anaemia, which can also prove fatal. Yet to date, screens have often been ignored in favour of using drugs and insecticides.

3 Sep 2009

Millennium's sNDA to be reviewed by the FDA

The Takeda Oncology Company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) based on long- term overall survival (OS) data from the landmark VISTA1 trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

3 Sep 2009

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

A key compound resupplies bone marrow with fast-acting stem cells that can more quickly rekindle blood cell production, according to a study published online today in the journal Blood. While the study was in mice, in the study authors say it has the potential to increase survival among patients with life-threatening blood cell shortages.

3 Sep 2009

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA’s Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar’s efficacy and safety in the proposed patient population.

2 Sep 2009

Children's Hospital Oakland converts to Masimo Rainbow SET Pulse CO-Oximetry technology

Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Children's Hospital & Research Center Oakland has completed its system-wide conversions to Masimo Rainbow SET Pulse CO-Oximetry technology.

2 Sep 2009

Cimzia approved for treating adult patients with rheumatoid arthritis

UCB Canada Inc. announced today that Health Canada has approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

1 Sep 2009

Rite Aid pharmacies to offer regular seasonal flu shots throughout the flu season

Many Rite Aid pharmacists have already been giving regular seasonal flu shots following the Centers for Disease Control and Prevention (CDC) advice that anyone who wishes to reduce the risk of getting the regular seasonal flu get a flu shot as soon as they are available.

31 Aug 2009

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease.

31 Aug 2009

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA’s Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.

29 Aug 2009

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

Medgenics is pleased to announce that one of the patients, who was treated with the Company’s EPODURE tissue Biopumps almost 11 months ago, continues to be effectively treated for anemia without a single erythropoietin (EPO) injection. This patient (#2) was dependent on frequent injections of the therapeutic protein (EPO) for the 18 months prior to receiving a single administration of 3 tiny EPODURE tissue Biopumps in the Company’s phase I/II anemia trial in Israel.

27 Aug 2009

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.

26 Aug 2009

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Alvine Pharmaceuticals, Inc. today announced that patient enrollment has begun in a Phase 2a, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ALV003 for use in the treatment of celiac disease.

26 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

USDA donates funds for teaching food safety awareness to AIDS patients

Researchers at the University of Illinois at Chicago School of Public Health have received a grant from the U.S. Department of Agriculture to educate AIDS patients on food safety.

25 Aug 2009

Lundbeck to launch Sabril in the US following FDA's NDA approval

Lundbeck Inc. (“Lundbeck”), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: LUN), announced today that the U.S. Food and Drug Administration (FDA) has granted two New Drug Application (NDA) approvals for Sabril® (vigabatrin) Tablets and Oral Solution. Lundbeck plans to launch Sabril in the United States in the third quarter.

24 Aug 2009

MedImmune, WPS and AYSO collaboratively launch a national health awareness campaign

MedImmune, Women's Professional Soccer (WPS) and the American Youth Soccer Organization (AYSO) today officially launched "Don't Play with the Flu,"((TM)) a national health awareness campaign that aims to highlight the importance of getting a seasonal influenza vaccination every year.

20 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

Genetic mutation that helps regulate high blood pressure is a cause of inherited kidney disease

The discovery provides insight into a protein, renin, that is important in blood pressure regulation, and reveals the cause of one type of inherited kidney disease occurring in adults and children, said co-investigator Anthony Bleyer, M.D., professor of internal medicine-nephrology at the School of Medicine.

19 Aug 2009

Anemia News and Research

Further Reading

Also in global health news: Africa measles eradication; water, food security in South Asia; MDR-TB in Mumbai; SADC summit; U.S. Cuba embargo

Adding screens to homes can cut malaria risk, study says

Mosquito screens prevent malaria

Millennium's sNDA to be reviewed by the FDA

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Children's Hospital Oakland converts to Masimo Rainbow SET Pulse CO-Oximetry technology

Cimzia approved for treating adult patients with rheumatoid arthritis

Rite Aid pharmacies to offer regular seasonal flu shots throughout the flu season

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

USDA donates funds for teaching food safety awareness to AIDS patients

Lundbeck to launch Sabril in the US following FDA's NDA approval

MedImmune, WPS and AYSO collaboratively launch a national health awareness campaign

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Genetic mutation that helps regulate high blood pressure is a cause of inherited kidney disease

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News